Senem Tekeoglu

Senem Tekeoglu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
STSenem Tekeoglu
Senem Tekeoglu
Purpose: Rheumatoid arthritis (RA) is linked to cardiovascular disease (CVD), due to chronic inflammation and traditional CVD risk factors. This study evaluates CVD and related risk factors in RA patients compared to age and gender-matched controls without inflammatory diseases, and differences within RA patients with and without CVD. Patients and Methods: This retrospective case-control study reviewed medical records of 405 RA patients (cases) and 950 control patients who attended rheumatology clinics in two branches of a private hospital between January 2021 and January 2024 to assess cardiovascular disease prevalence and associated risk factors. Results: RA patients, with a mean age of 59 (± 23) years, disease duration of 89.5 months, and a female-to-male ratio of 4:1, exhibited a higher prevalence of CVD compared to controls (p = 0.01), despite similar classical risk factors. Logistic regression identified RA as an independent risk factor for CVD (p = 0.02, odds ratio = 1.9). RA patients with CVD were typically older males (p < 0.001), presenting with higher rates of hypertension (p < 0.001), hyperlipidemia (p < 0.001), diabetes (p = 0.002), and chronic kidney disease (p < 0.001). Arrhythmias (p < 0.001) and heart failure (p < 0.001) were prevalent among this subgroup, along with elevated creatinine levels and reduced glomerular filtration rates (p < 0.001 each). Treatment patterns indicated lower use of methotrexate (p = 0.003) and higher use of leflunomide (p = 0.02) among RA patients with CVD. Conclusion: CVD in RA patients is multifactorial, involving both chronic systemic inflammation and classical CVD risk factors. Further research is necessary to advance our understanding of CVD in RA patients and to optimize treatment strategies for improved outcomes.

25 April 2019 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
DKDuygu Temiz Karadag
Duygu Temiz Karadag
TSTayfun Sahin
Tayfun Sahin
STSenem Tekeoglu
Senem Tekeoglu
OIOzlem Ozdemir Isik
Ozlem Ozdemir Isik
AYAyten Yazici
Ayten Yazici
ACAyse Cefle
Ayse Cefle

15 February 2024 in The Journal of Sexual Medicine
Verified
Journal Article
Open access
OIOzlem Ozdemir Isik
Ozlem Ozdemir Isik
DKDuygu Temiz Karadag
Duygu Temiz Karadag
STSenem Tekeoglu
Senem Tekeoglu
AYAyten Yazici
Ayten Yazici
ACAyse Cefle
Ayse Cefle
Background: Sjögren’s syndrome (SS) is an autoimmune systemic disease affecting many organs and systems, such as genital system. Aim: This study aimed to present the gynecological symptoms of patients who were followed up in an outpatient clinic because of primary Sjögren’s syndrome (pSS) and secondary Sjögren’s syndrome (sSS) and to show how the disease affected sexuality. Methods: This study is a cross-sectional study conducted between 2019 and 2020. The study sample consisted of 60 pSS patients, 42 sSS patients, and 52 healthy control subjects. Outcomes: All the participants were questioned about sexuality, and completed the 36-item Short Form Survey, Hospital Anxiety and Depression Scale, Health Assessment Questionnaire, and Modified Hill questionnaire. Results: The patients had a mean age of 55.6 ± 11.85 years in pSS, 59.39 ± 11.18 years in sSS, and 56.1 ± 10.46 years in healthy control subjects. Vaginal and vulvar dryness and dyspareunia were present at a significantly higher rate in SS, especially in pSS, compared with the control subjects. The Health Assessment Questionnaire score was significantly lower in the pSS group than in the sSS group. Arthralgia, myalgia, and fatigue were prominent in all SS patients. Clinical Implications: Gynecological symptoms, sexual ability, and the effects of the disease on sexuality should be questioned in all SS patients. Strengths and Limitations: It is very important that we evaluate the gynecological symptoms of both pSS and sSS patients and the effect of the disease on these symptoms. The small number of patients and healthy control subjects is a limitation. Conclusion: The gynecological and musculoskeletal symptoms negatively affected sexuality in patients with pSS and sSS, and the negative effect of the disease on sexuality was more pronounced in the pSS group.

14 August 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
OIOzlem Ozdemir Isik
Ozlem Ozdemir Isik
DKDuygu Temiz Karadag
Duygu Temiz Karadag
STSenem Tekeoglu
Senem Tekeoglu
AYAyten Yazici
Ayten Yazici
KÇKıvanç Çefle
Kıvanç Çefle
ACAyse Cefle
Ayse Cefle

29 November 2024 in Medicine
Verified
Journal Article
Open access
STSenem Tekeoglu
Senem Tekeoglu
Rheumatic diseases present unique challenges in the elderly, with changes in the immune system contributing to varied clinical presentations. More individuals are now living with chronic diseases due to greater life expectancy, but there is a lack of real-world data about rheumatic diseases and comorbidities in older people. This study aimed to investigate disease types, comorbidities, treatments, and mortality in geriatric patients in comparison to non-geriatric patients at a rheumatology clinic. This retrospective observational cohort study reviewed the medical records of 2610 patients from January 2021 to January 2024 at 2 branches of a private hospital’s rheumatology clinics. Demographic information and data on rheumatic diseases, noninflammatory conditions, treatments, comorbidities, and mortality were collected, and geriatric patients were compared to non-geriatric patients. Geriatric patients (n = 515) had a significantly higher prevalence of rheumatoid arthritis (50.6% vs 28.8%, P < .001), polymyalgia rheumatica (11.1% vs 0.2%, P < .001), and crystal arthritis (19.6% vs 8.8%, P < .001), with more frequent geriatric-onset cases. Osteoarthritis was also more prevalent in geriatric patients (51.2% vs 11.3%, P < .001), while fibromyalgia was more common in the non-geriatric group (15.9% vs 4.1%, P < .001). Geriatric patients experienced higher rates of comorbidities, including hypertension (72.4% vs 17.8%, P < .001), diabetes (33.6% vs 12.1%, P < .001), and osteoporosis (64.9% vs 35.4%, P < .001). These patients used more corticosteroids (74.5% vs 44%, P < .001), and conventional synthetic disease-modifying antirheumatic drugs (62.4% vs 49.4%, P < .001) but fewer biological disease-modifying antirheumatic drugs (9.2% vs 23.1%, P < .001). Mortality rates were significantly higher in geriatric patients (6% vs 0.3%), with cancer (P = .001), ischemic heart disease (P = .04), heart failure (P = .01), chronic kidney disease (P = .02), and interstitial lung disease (P = .01) being associated with increased mortality. Geriatric rheumatology should receive greater focus in future research to help address the anticipated increases in demand and to develop tailored management strategies for elderly patients with rheumatic diseases and comorbidities.

23 January 2024 in Lupus
Verified
Journal Article
Closed access
STSenem Tekeoglu
Senem Tekeoglu
DKDuygu Temiz Karadag
Duygu Temiz Karadag
OIOzlem Ozdemir Isik
Ozlem Ozdemir Isik
AYAyten Yazici
Ayten Yazici
ACAyse Cefle
Ayse Cefle
Objective: This retrospective study aimed to conduct a comprehensive analysis of Turkish Systemic Lupus Erythematosus (SLE) patients of Caucasian ethnicity, focusing on their clinical, immunological, and therapeutic characteristics, damage accural and mortality. Patients and Methods: We carried out a retrospective assessment of 300 SLE patients diagnosed between 2001 and 2017 at Kocaeli University Rheumatology Clinic. Demographic data, clinical manifestations, immunological profiles, treatment approaches, disease-related damage, and survival information were collected. Results: The study population had a significant female predominance (89%) with a mean age of disease onset of 35.4 (SD:13.3) years. Hematological (72.6%) and mucocutaneous (72%) manifestations were the most common clinical findings, followed by arthritis (66.3%). Females had higher frequency of photosensitivity (p = 0.019), malar rash (p < 0.001), and alopecia (p = 0.014). Anti-dsDNA antibodies were detected in 61.6% of patients, while 57% of patients had hypocomplementemia. Secondary antiphospholipid syndrome was observed in 15.3% of patients; the most common manifestations included deep venous thrombosis (32.6%) and cerebrovascular accidents (30.4%). Lupus Nephritis (LN) affected 40.3% of the cohort. The most common pathologic finding was Class IV LN (30.5%). Eventually, 13 (4.3%) patients developed chronic kidney disease (CKD) and 4 had renal replacement therapies. Patients with LN had higher usage of pulse steroids, azathioprin, mycophenolate mofetil, cyclophosphamide, and rituximab (p < 0.001 for each). In the juvenile-onset group (n = 31, 10.3%), an increased occurrence of malar rash (p = 0.009), nephritis (p = 0.034), hypocomplementemia (p = 0.001), positive anti-dsDNA (p = 0.007), anti-Sm (p = 0.046), anti-rib-P (p = 0.014) antibodies were observed. At least one damage parameter was observed in 32.6% patients with musculoskeletal manifestations being the most common. Thirteen patients were diagnosed with various malignancies, with cervical cancer being the most common (4 cases). The total 5 and 10-year survival rates were 92.5% and 86.7%, respectively. However, patients with CKD, had lower survival rates; 75% at 3 years and 60% at 15 years. Regression analysis demonstrated an association of CKD and history of infections with decreased survival (p = 0.02, each). Conclusion: Ethnicity and geography influence the clinical diversity of SLE. Recognizing these disparities is crucial for tailoring patient care. Future inception cohort studies in Turkish SLE patients are necessary to address the limitations of retrospective research.